Prior to initiating therapy for chronic phase CML, determination of the patient's Sokal or Hasford risk score is recommended. The Sokal score is based on the patient's age, spleen size, peripheral platelet count, and blast percentage in peripheral blood, whereas the Hasford score is calculated from peripheral eosinophil and basophil counts as well as the Sokal parameters. Either of these scores helps in stratifying patients with chronic phase CML into low, intermediate, or high risk, which will guide the choice of therapy. In addition to the risk score, the toxicity profile of available agents and patient comorbidities are also important considerations that inform treatment decisions.
The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically improved the duration of hematologic and cytogenetic remissions in patients. In fact, many patients with chronic phase CML who are treated with TKIs may approach normal life expectancy.
According to 2022 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, allogeneic stem cell transplant is no longer a recommended first-line treatment option for patients with chronic phase CML.
Learn more about treatment protocols for chronic phase CML.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Chronic Myelogenous Leukemia Management - Medscape - Sep 21, 2022.